A patent review of EZH2 inhibitors from 2017 and beyond.

Expert opinion on therapeutic patents(2023)

引用 0|浏览5
暂无评分
摘要
In recent years, a great number of structurally diverse EZH2 inhibitors have been identified, including EZH2 reversible inhibitors, EZH2 irreversible inhibitors, EZH2-based dual inhibitors and EZH2 degraders. Despite the multiple challenges, EZH2 inhibitors offer promising potential for the treatment of various diseases, such as cancers.
更多
查看译文
关键词
Cancer,Degrader,EZH2 inhibitor,Patent,Tazemetostat
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要